Pharmacy Act, 1991
Loi de 1991 sur les pharmaciens

ONTARIO REGULATION 202/94

GENERAL

Consolidation Period: From December 15, 2016 to the e-Laws currency date.

Last amendment: 452/16.


This Regulation is made in English only.

PART VII.3
CONTROLLED ACTS

INTERPRETATION

31. In this Part,
“adapt” means to change a patient’s prescription respecting,
   (a) the dose of the prescribed drug,
   (b) the dosage form of the prescribed drug,
   (c) the directions for use of the prescribed drug, or
   (d) the route of administration for taking the prescribed drug,
   but does not include therapeutic substitution;
“Part A pharmacist” means a member who holds a certificate of registration as a pharmacist and who is listed in Part A of the
   register;
“point of care test” means a diagnostic test performed on a patient sample at the site of patient care;
“prescriber” means a person who is authorized under the laws of a province or territory of Canada to give a prescription
   within the scope of his or her practice of a health profession;
“prescription” means a direction from a prescriber directing the dispensing of a drug or mixture of drugs for a specific
   patient;
“renew” means to provide a patient with a prescription that repeats a prescription previously provided to that patient;
“therapeutic substitution” means the substitution of a drug that contains chemically different active ingredients that are
   considered to be therapeutically equivalent.

32. (1) Where the provisions of this Part are inconsistent with a law of Canada respecting prescriptions, including those
   related to a targeted substance, the law of Canada shall prevail and the provisions of this Part to the extent they are
   inconsistent with that law shall not apply.

   (2) Where the provisions of this Part are inconsistent with the provisions of the Narcotics Safety and Awareness Act, 2010,
   the provisions of that Act shall prevail and the provisions of this Part, to the extent they are inconsistent with that Act, shall
   not apply.

CONTROLLED ACTS

33. A member shall not perform a controlled act under paragraph 2, 3, 4 or 5 of subsection 4 (1) of the Act except in
   accordance with this Part.

34. (1) For the purposes of paragraph 2 of subsection 4 (1) of the Act, a member referred to in subsection (2) who meets
   all the requirements in subsection (3) is authorized to perform the following acts:

   1. Administering a substance specified in Schedule 1 by injection to a patient through a route other than direct
      intravenous, intravenous push, intravenous bolus, intrathecal, intraarticular, intracardiac, intraspinal, intraocular, and
      intracavernous.

   2. Administering a substance specified in Schedule 2 by inhalation to a patient.
(2) A Part A pharmacist, an intern or a registered pharmacy student is authorized to perform an act provided for in subsections (1), (4) and (5), subject to the terms, conditions and limitations imposed on his or her certificate of registration.

(3) A member may only perform an act provided for in subsection (1) if he or she complies with the following:

1. The member must receive an informed consent from the patient or his or her authorized agent before performing the act.
2. The member shall ensure that he or she only performs the act in an environment that is clean, safe, private and comfortable for the patient.
3. The member shall ensure that appropriate infection control procedures are in place.
4. The member must possess sufficient knowledge, skill and judgment respecting the substance to be administered, and sufficient understanding of the condition of the patient, to be able to administer the substance safely.
5. The member must consider whether administering a substance by injection or inhalation to the patient is appropriate, given the known risks and benefits to the patient and the safeguards and resources available to safely manage the outcome after administration and any other relevant circumstances.
6. The member must maintain a patient record that includes,
   i. the name and address of the patient,
   ii. the name and address of the member,
   iii. the date the act was performed,
   iv. the name, strength (where applicable) and quantity of the substance that the member administered to the patient,
   v. the circumstances relating to the administration of the substance to the patient and any adverse reaction experienced by the patient, and
   vi. confirmation that an informed consent was given by the patient or his or her authorized agent.
7. Where the act is performed for a purpose other than patient education and demonstration, the member must notify the patient’s primary care provider (if any) within a reasonable time that the member performed the act and provide details respecting the act.

(4) For the purposes of paragraph 2 of subsection 4 (1) of the Act, a member referred to in subsection (2) is authorized to administer influenza vaccine by injection to a patient who is two years of age or older, if the member,

(a) administers the vaccine in accordance with Ontario’s Universal Influenza Immunization Program as described on the Ministry’s website; and
(b) meets all the requirements in paragraphs 1 to 6 of subsection (3).

(5) For the purposes of paragraph 2 of subsection 4 (1) of the Act, a member referred to in subsection (2) is authorized to administer a vaccine from one of the vaccines specified in Schedule 3 by injection to a patient who is five years of age or older, if the member,

(a) meets all the requirements in paragraphs 1 to 6 of subsection (3); and
(b) notifies the patient’s primary care provider (if any) within a reasonable time that the member administered a vaccine to the patient and provides details respecting the administration.

35. (1) For the purposes of paragraph 3 of subsection 4 (1) of the Act, a member referred to in subsection (3) who complies with the other requirements of this section is authorized to prescribe the following specified drugs:

1. Varenicline Tartrate.
2. Bupropion Hydrochloride.

(2) A drug mentioned in subsection (1) may only be prescribed by a member for the sole purpose of smoking cessation.

(3) A Part A pharmacist, an intern or a registered pharmacy student is authorized to perform the act provided for in subsection (1), subject to the terms, conditions and limitations imposed on his or her certificate of registration.

(4) A member may only prescribe a drug under this section if he or she,

(a) possesses sufficient knowledge, skill and judgment respecting the drug and the patient’s condition to prescribe the drug for the patient;
(b) has considered whether prescribing the drug for the patient is appropriate, given the known risks and benefits of prescribing the drug for the patient and other relevant factors respecting the patient;
(c) gives the prescription to the patient or his or her authorized agent;
(d) advises the patient or his or her authorized agent, at the time of giving the prescription, that he or she may elect to take it to a pharmacy of his or her choosing for dispensing;

(e) notifies the patient’s primary care provider (if any) within a reasonable time, that the member prescribed a drug for the patient and provides details respecting the prescription; and

(f) complies with the additional requirements under sections 37 and 38.

36. (1) For the purposes of paragraph 4 of subsection 4 (1) of the Act, a member referred to in subsection (3) who complies with the other provisions of this section is authorized to perform the following acts:

1. Adapting a patient’s prescription.

2. Renewing a patient’s prescription for the purpose of continuity of care.

(2) Subsection (1) does not authorize a member referred to in subsection (3) to adapt or renew a prescription for a controlled substance as defined in the Controlled Drugs and Substances Act (Canada) or a drug designated as a monitored drug by the regulations under the Narcotics Safety and Awareness Act, 2010.

(3) A Part A pharmacist, an intern or a registered pharmacy student is authorized to perform an act provided for in subsection (1), subject to the terms, conditions and limitations imposed on his or her certificate of registration.

(4) A member may only perform an act provided for in subsection (1) if he or she complies with the following:

1. The member must either possess the patient’s prescription to be adapted or renewed or,
   i. receive a copy of the prescription directly from the pharmacy where the prescription was dispensed to the patient,
   ii. be satisfied based on verbal confirmation from a pharmacist at the pharmacy where the prescription was dispensed to the patient as to the existence and details of the prescription, or
   iii. have access to the medical record that contains information about the prescription.

2. If the member is renewing a prescription, he or she must not prescribe a quantity of the drug that exceeds the lesser of,
   i. the quantity that was originally prescribed, including any refills that were authorized by the prescriber, and
   ii. a twelve months’ supply.

3. The member must, within a reasonable time, notify the prescriber identified on the prescription adapted or renewed by the member, as well as the patient’s primary care provider if the member knows that the patient has such a care provider other than the prescriber, providing details about the patient’s prescription, when the member,
   i. renews a patient’s prescription, or
   ii. adapts a patient’s prescription, if, in the member’s opinion,
      A. adapting the prescription is clinically significant in relation to the patient, or
      B. the notification is necessary to support the patient’s care.

4. At the time that the member adapts or renews the patient’s prescription, the member must advise the patient or his or her authorized agent,
   i. that he or she is entitled to the prescription, and
   ii. that he or she may take the prescription to a pharmacy of his or her choosing for dispensing.

5. The member must comply with the additional requirements under sections 37 and 38.

37. A member who performs an act provided for in section 35 or 36 must ensure that the following information is recorded on the prescription:

1. The name and address of the patient for whom the drug is prescribed.

2. The name, strength (where applicable) and quantity of the prescribed drug.

3. Directions for the use of the drug, including its dose, frequency, route of administration and any special instructions.

4. The name, address, telephone number and College registration number of the member issuing the prescription.

5. The date the prescription was issued by the member.

6. If applicable, reference to the prescription that the member adapted or renewed, including the name and contact details of the original prescriber.

7. The number of refills that the member authorized, if applicable.

8. Any other information required by law.
38. A member who performs an act under section 35 or 36 must maintain a patient record that includes details of the member’s rationale for his or her decision to act under section 35 or 36 and the following information, if applicable:

1. Reference to, or a copy of, the patient’s prescription that the member renewed or adapted, including the name and contact information of the prescriber.

2. A copy of the prescription that the member gave to the patient or his or her authorized agent under clause 35 (4) (c) or that the member gave to the patient or his or her authorized agent to take to a pharmacy of their choosing under paragraph 4 of subsection 36 (4).

3. A record of the results of laboratory or other tests that the member considered in making the decision to act under section 35 or 36.

4. The date on which the member notified the following persons, as applicable, and the method by which the notification occurred:
   i. The patient’s primary care provider notified under clause 35 (4) (e) or paragraph 3 of subsection 36 (4).
   ii. The patient’s prescriber notified under paragraph 3 of subsection 36 (4).

39. (1) For the purposes of paragraph 5 of subsection 4 (1) of the Act, and subject to subsection (3), a member referred to in subsection (2) who meets all the requirements in subsection (4) is authorized to perform the act of piercing a patient’s dermis with a lancet-type device to obtain blood.

(2) A member who is a Part A pharmacist, an intern, a registered pharmacy student or a pharmacy technician is authorized to perform the act provided for in subsection (1), subject to the terms, conditions and limitations imposed on his or her certificate of registration.

(3) A pharmacy technician shall not perform the act provided for in subsection (1) unless,
   (a) a Part A pharmacist is physically present on the premises at the time when the pharmacy technician performs the act;
   (b) the pharmacy technician is under the direction of a Part A pharmacist at the time when the pharmacy technician performs the act; and
   (c) where the act is performed to administer a point of care test, a Part A pharmacist interprets the results of the test and makes the professional decision arising from the results of the test.

(4) A member may only perform the act provided for in subsection (1) if he or she complies with the following:
   1. The member must receive an informed consent from the patient or his or her authorized agent before performing the act.
   2. The member shall ensure that he or she only performs the act in an environment that is clean, safe, private and comfortable for the patient.
   3. The member shall ensure that appropriate infection control procedures are in place.
   4. The member must possess the knowledge, skill and judgment respecting the performance of the act and understand the condition of the patient, to perform it safely and effectively.
   5. The member must consider whether performing the act on the patient is appropriate, given the known risks and benefits to the patient and the safeguards and resources available to safely manage the outcome and any other relevant circumstances.
   6. The member must maintain a patient record that includes,
      i. the name and address of the patient,
      ii. the name and address of the member,
      iii. the date the act was performed,
      iv. the circumstances relating to the act and any adverse reaction experienced by the patient,
      v. where the member performed the act to administer a point of care test, the results of the test,
      vi. the professional decision arising from the results of the point of care test and the rationale for the decision, and
      vii. confirmation that an informed consent was given by the patient or his or her authorized agent.

7. Where the act is performed for a purpose other than patient education and demonstration, the member must notify the patient’s primary care provider (if any) within a reasonable time that the member performed the act and provide details respecting the act.
SCHEDULE 1
INJECTED SUBSTANCES – BY DRUG LIST

(Arranged by American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification)

1. 8:00 Anti-infective Agents
   i. 8:12 Antibacterials
      A. 8:12.02 Aminoglycosides
         1. Amikacin
         2. Gentamicin
      B. 8:12.06.04 First Generation Cephalosporins
         1. Cefazolin
      C. 8:12.06.12 Third Generation Cephalosporins
         1. Cefotaxime
         2. Ceftazidime
         3. Ceftriaxone
      D. 8:12.06.16 Fourth Generation Cephalosporins
         1. Cefepime
      E. 8:12.07.08 Carbapenems
         1. Ertapenem
      F. 8:12.07.12 Cephamycins
         1. Cefoxitin
      G. 8:12.16.04 Natural Penicillins
         1. Penicillin G
      H. 8:12.16.08 Aminopenicillins
         1. Ampicillin
      I. 8:12.16.12 Pencillinase-Resistant Penicillins
         1. Cloxacillin
      J. 8:12.28.20 Lincomycins
         1. Clindamycin
      K. 8:12.28.28 Polymyxins
         1. Colistin
   ii. 8:18 Antivirals
      A. 8:18.08.04 HIV Entry and Fusion Inhibitors
         1. Enfuvirtide
      B. 8:18.20 Interferons
         1. Interferon Alfa-2b
         2. Peginterferon alfa-2a
         3. Peginterferon Beta-1a
   2. 10:00 Antineoplastic Agents
      1. Goserelin
      2. Leuprolide
      3. Methotrexate
      4. Fulvestrant
5. Triptorelin acetate
6. Rituximab

3. 12:00 Autonomic Drugs
   i. 12:08.08 Antimuscarinic Antispasmodics
      1. Atropine
   ii. 12:12 Sympathomimetic (Adrenergic) Agents
       A. 12:12.12 Alpha- and Beta-Adrenergic Agonists
          1. Scopolamine
          2. Hyoscine
          3. Glycopyrrolate
          4. Epinephrine
       iii. 12:16 Sympatholytic (Adrenergic Blocking) Agents
            1. Dihydroergotamine

4. 20:00 Blood Formation and Coagulation
   i. 20:12 Coagulants and Anticoagulants
      A. 20:12.04 Anticoagulants
         1. Dalteparin
         2. Danaparoid
         3. Enoxaparin
         4. Fondaparinux
         5. Heparin
         6. Nadroparin
         7. Tinzaparin
      ii. 20:16 Hematopoietic Agents
          1. Ancestim
          2. Darbepoetin alfa
          3. Epoetin alfa
          4. Filgrastim
          5. Pegfilgrastim
          6. Romiplostim
      iii. 20:28.92 Antihemorrhagic Agents, Miscellaneous
           1. Emicizumab

5. 24:00 Cardiovascular Drugs
   i. 24:06.24 Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors
      1. Alirocumab
      2. Evolocumab

6. 28:00 Central Nervous System Agents
   i. 28:08 Analgesics and Antipyretics
      A. 28:08.08 Opiate Agonists
         1. Codeine
         2. Hydromorphone
         3. Morphine
B. 28:08.12 Opiate Partial Agonists
   1. Nalbuphine
   2. Pentazocine

ii. 28:10 Opiate Antagonists
   1. Naloxone

iii. 28:16 Psychotherapeutic Agents
   A. 28:16.08 Antipsychotics
      1. Haloperidol
      2. Methotrimeprazine
      3. Aripiprazole
      4. Flupentixol
      5. Methotrimeprazine
      6. Paliperidone
      7. Risperidone
      8. Zuclopenthixol
      9. Fluphenazine
     10. Olanzapine

iv. 28:24.08 Benzodiazepines
   1. Lorazepam
   2. Diazepam
   3. Midazolam

v. 28:32 Antimigraine Agents
   A. 28:32:12 Calcitonin-Gene-Related Peptide (CGRP) Antagonists
      1. Erenumab
   B. 28:32.28 Selective Serotonin Agonists
      1. Sumatriptan

vi. 28:36 Antiparkinsonian Agents
   A. 28:36.20.08 Nonergot-derivative Dopamine Receptor Agonists
      1. Apomorphine
   B. 28:36.08 Anticholinergic Agents
      1. Benztropine

vii. 28:92 Miscellaneous Central Nervous System Agents
    1. Inotersen

7. 40:00 Electrolytic, Caloric, and Water Balance
   i. 40:12 Replacement Preparations
      1. Normal saline

8. 44:00 Enzymes
   1. Asfotase Alfa

9. 48:00 Respiratory Tract Agents
   i. 48:92 Respiratory Tract Agents, Miscellaneous
      1. Omalizumab
      2. Benralizumab
10. 56:00 Gastrointestinal Drugs
   i. 56:22 Antiemetics
      A. 56:22.08 Antihistamines
         1. Dimenhydrinate
   ii. 56:32 Prokinetic Agents
      1. Metoclopramide
   iii. 56:92 GI Drugs, Miscellaneous
        1. Certolizumab Pegol
        2. Methylnaltrexone
11. 64:00 Heavy Metal Antagonists
    1. Deferoxamine
12. 68:00 Hormones and Synthetic Substitutes
    i. 68:04 Adrenals
       1. Betamethasone
       2. Tetracosactide
       3. Hydrocortisone
       4. Dexamethasone
       5. Prednisolone
       6. Methylprednisolone
    ii. 68:08 Androgens
        1. Testosterone
    iii. 68:18 Gonadotropins
        1. Follitropin-alpha
        2. Follitropin-beta
        3. Follitropin-delta
        4. Gonadotropin-chorionic
        5. Gonadotropin-chorionic-alfa
        6. Gonadotropin-human
        7. Lutropin-alfa
        8. Menotropins
    iv. 68:20 Antidiabetic Agents
        1. Exenatide
        2. Insulins
        3. Liraglutide
        4. Dulaglutide
        5. Lixisenatide
        6. Semaglutide
    v. 68:22 Antihypoglycemic Agents
       A. 68:22:12 Glycogenolytic Agents
          1. Glucagon
    vi. 68:24 Parathyroid
        1. Calcitonin Salmon
2. Teriparatide

vii. 68:28 Pituitary
   1. Desmopressin
   2. Vasopressin

viii. 68:29:04 Somatostatin Agonists
   1. Pasireotide

ix. 68:30 Somatotropin Agonists and Antagonists
   A. 68:30.04 Somatotropin Agonists
      1. Somatropin
      2. Tesamorelin
   B. 68:30.08 Somatotropin Antagonists
      1. Pegvisomant

x. 68:32 Progestins
   1. Medroxyprogesterone
   2. Progesterone

xi. 68:36:04 Thyroid Agents
   1. Levothyroxine

13. 72:00 Local Anesthetics
   1. Lidocaine
   2. Prilocaine
   3. Articaine
   4. Bupivacaine
   5. Mepivacaine

14. 84:92 Misc. Skin and Mucous Membrane Agents
   1. Brodalumab
   2. Dupilumab
   3. Guselkumab
   4. Ixekizumab
   5. Risankizumab
   6. Secukinumab

15. 88:00 Vitamins
   i. 88:08 Vitamin B Complex
      1. Cyanocobalamin
      2. Folic Acid
      3. Pyridoxine
      4. Thiamine
   ii. 88:12 Vitamin C
      1. Ascorbic Acid
   iii. 88:24 Vitamin K Activity
      1. Vitamin K

16. 92:00 Miscellaneous Therapeutic Agents
   i. 92:20 Biologic Response Modifiers
1. Denosumab
2. Glatiramer
3. Interferon-Beta-1A
4. Interferon-Beta-1B

ii. 92:32 Complement Inhibitors
   1. Icatibant
   2. Lanadelumab

iii. 92:36 Disease-modifying Antirheumatic Drugs
    1. Abatacept
    2. Adalimumab
    3. Anakinra
    4. Etanercept
    5. Golimumab
    6. Ustekinumab
    7. Sarilumab
    8. Tocilizumab

iv. 92:40 Gonadotropin-releasing Hormone Antagonists
    1. Cetrorelix
    2. Ganirelix

v. 92:44 Immunosuppressive Agents
   1. Belimumab
   2. Mepolizumab

vi. 92:92 Other Miscellaneous Therapeutic Agents
    7. Octreotide
    8. Lanreotide

17. Miscellaneous
   1. Sterile Water for Injection (Diluent)

**SCHEDULE 2**
**INHALED SUBSTANCES – BY DRUG LIST**

(Arranged by American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification)

1. 8:00 Anti-infective Agents
   i. 8:18 Antivirals
      A. 8:18.28 Neuraminidase Inhibitors
         1. Zanamivir
   ii. 8:12 Antibacterials
      A. 8:12.07.16 Monobactams
         1. Tobramycin
         2. Aztreonam
      B. 8:12.18 Quinolones
         1. Levofoxacin
2. 12:00 Autonomic Drugs
   i. 12:08 Anticholinergic Agents
      A. 12:08.08 Antimuscarinics/Antispasmodics
         1. Ipratropium
         2. Tiotropium
         3. Umeclidinium
         4. Aclidinium
   ii. 12:12 Sympathomimetic (Adrenergic) Agents
       A. 12:12.08.12 Selective Beta2- Adrenergic Agonists
          1. Formoterol
          2. Salbutamol
          3. Salmeterol
          4. Terbutaline
          5. Vilaanterol
          6. Indacaterol
          7. Olodaterol
   iii. 12:16 Sympatholytic (Adrenergic Blocking) Agents
        A. 12:16.04.04 Non-Selective alpha-Adrenergic Blocking Agents
           1. Dihygroergotamine
   iv. 12:92 Autonomic Drugs, Miscellaneous
       1. Nicotine
3. 28:00 Central Nervous System Agents
   i. 28:08 Analgesics and Antipyretics
      A. 28:08.12 Opiate Partial Agonists
         1. Butorphanol
   ii. 28:32 Antimigraine Agents
       A. 28:32.28 Selective Serotonin Agonists
          1. Sumatriptan
          2. Zolmitriptan
4. 40:00 Electrolytic, Caloric, and Water Balance
   i. 40:12 Replacement Preparations
      1. Sodium chloride
5. 48:00 Respiratory Tract Agents
   i. 48:12.08 Anticholinergic Agents
      1. Glycopyrronium
   ii. 48:24 Mucolytic Agents
       1. Dornase alfa
6. 52:00 Eye, Ear, Nose and Throat (EENT) Preparations
   i. 52:02 Antiallergic Agents
      1. Sodium Cromoglycate
      2. Levocabastine
   ii. 52:08 Anti-inflammatory Agents
A. 52:08.08 Corticosteroids
   1. Beclomethasone
   2. Budesonide
   3. Ciclesonide
   4. Flunisolide
   5. Fluticasone
   6. Mometasone
   7. Triamcinolone

iii. 52:32 Vasoconstrictors
   1. Oxymetazoline
   2. Phenylephrine
   3. Xylometazoline

7. 68:00 Hormones and Synthetic Substitutes
   i. 68:18 Gonadotropins
      1. Buserelin
      2. Nafarelin
   ii. 68:24 Parathyroid
      1. Calcitonin Salmon
   iii. 68:28 Pituitary
      1. Desmopressin
      2. Vasopressin

8. 92:00 Miscellaneous Therapeutic Agents
   i. 92:12 Antidotes
      1. Acetylcysteine

SCHEDULE 1
INJECTED SUBSTANCES – BY DRUG CATEGORY
(Arranged by American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification)

1. 8:00 Anti-infective Agents
   i. 8:12 Antibacterials
   ii. 8:18 Antivirals

2. 10:00 Antineoplastic Agents

3. 12:00 Autonomic Drugs
   i. 12:08 Antimuscarinic Antispasmodics
   ii. 12:12 Sympathomimetic (Adrenergic) Agents
   iii. 12:16 Sympatholytic (Adrenergic Blocking) Agents

4. 20:00 Blood Formation and Coagulation
   i. 20:12 Coagulants and Anticoagulants
   ii. 20:16 Hematopoietic Agents
iii. 20:28.92 Antihemorrhagic Agents, Miscellaneous

5. 24:00 Cardiovascular Drugs
   i. 24:06.24 Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors

6. 28:00 Central Nervous System Agents
   i. 28:08 Analgesics and Antipyretics
   ii. 28:10 Opiate Antagonists
   iii. 28:16 Psychotherapeutic Agents
   iv. 28:24 Benzodiazepines
   v. 28:32 Antimigraine Agents
   vi. 28:36 Antiparkinsonian Agents
   vii. 28:92 Miscellaneous Central Nervous System Agents

7. 40:00 Electrolytic, Caloric, and Water Balance
   i. 40:12 Replacement Preparations

8. 44:00 Enzymes

9. 48:00 Respiratory Tract Agents
   i. 48:92 Respiratory Tract Agents, Miscellaneous

10. 56:00 Gastrointestinal Drugs
    i. 56:22 Antiemetics
    ii. 56:32 Prokinetic Agents
    iii. 56:92 GI Drugs, Miscellaneous

11. 64:00 Heavy Metal Antagonists

12. 68:00 Hormones and Synthetic Substitutes
    i. 68:04 Adrenals
    ii. 68:08 Androgens
    iii. 68:18 Gonadotropins
    iv. 68:20 Antidiabetic Agents
    v. 68:22 Antihypoglycemic Agents
    vi. 68:24 Parathyroid
    vii. 68:28 Pituitary
    viii. 68:29:04 Somatostatin Agonists
    ix. 68:30 Somatotropin Agonists and Antagonists
    x. 68:32 Progestins
       1. Medroxyprogesterone
       2. Progesterone
xi. 68:36:04 Thyroid Agents

13.  72:00 Local Anesthetics

14.  84:92 Misc. Skin and Mucous Membrane Agents

15.  88:00 Vitamins
    i.  88:08 Vitamin B Complex
    ii.  88:12 Vitamin C
    iii.  88:24 Vitamin K Activity

16.  92:00 Miscellaneous Therapeutic Agents
    i.  92:20 Biologic Response Modifiers
    ii.  92:32 Complement Inhibitors
    iii.  92:36 Disease-modifying Antirheumatic Drugs
    iv.  92:40 Gonadotropin-releasing Hormone Antagonists
    v.  92:44 Immunosuppressive Agents
    vi.  92:92 Other Miscellaneous Therapeutic Agents

17.  Miscellaneous

SCHEDULE 2
INHALED SUBSTANCES – BY DRUG CATEGORY
(Arranged by American Hospital Formulary Service (AHFS) Pharmacologic-Therapeutic Classification)

1.  8:00 Anti-infective Agents
    i.  8:18 Antivirals
    ii.  8:12 Antibacterials

2.  12:00 Autonomic Drugs
    i.  12:08 Anticholinergic Agents
    ii.  12:12 Sympathomimetic (Adrenergic) Agents
    iii.  12:16 Sympatholytic (Adrenergic Blocking) Agents
    iv.  12:92 Autonomic Drugs, Miscellaneous

3.  28:00 Central Nervous System Agents
    i.  28:08 Analgesics and Antipyretics
    ii.  28:32 Antimigraine Agents

4.  40:00 Electrolytic, Caloric, and Water Balance
    i.  40:12 Replacement Preparations

5.  48:00 Respiratory Tract Agents
i. 48:12.08 Anticholinergic Agents
ii. 48:24 Mucolytic Agents

6. 52:00 Eye, Ear, Nose and Throat (EENT) Preparations
   i. 52:02 Antiallergic Agents
   ii. 52:08 Anti-inflammatory Agents
   iii. 52:32 Vasoconstrictors

7. 68:00 Hormones and Synthetic Substitutes
   i. 68:18 Gonadotropins
   ii. 68:28 Pituitary

8. 92:00 Miscellaneous Therapeutic Agents
   i. 92:12 Antidotes
      1. Acetylcysteine